Blanket Purchase Agreement V797D70251-36E79718A0004

The U.S. Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc. a single-award Blanket Purchase Agreement (BPA) under the GSA Pharmaceuticals and Drugs Schedule. The BPA has a ceiling value of $1,378,620 and a period of performance from May 22, 2020 to May 21, 2025. The purpose of this contract is to provide the VA healthcare system with a stable supply of the specialty pharmaceutical product pexidartinib, marketed under the brand name TURALIO, for the treatment of tenosynovial giant...

This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA), Network Contracting Office 9 (NCO 9), to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $49.2 million BPA is for the procurement of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), a radiopharmaceutical used in cancer treatment and diagnostic imaging. The BPA is established under the Pharmaceuticals...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the Department of Veterans Affairs (VA) to Daiichi Sankyo, Inc., a pharmaceutical manufacturer. The single-award BPA, valued at $80,206.95, provides a mechanism for VA healthcare facilities nationwide to efficiently procure the specialty drug pexidartinib (marketed as TURALIO) in various dosage forms. Pexidartinib is used to treat tenosynovial giant cell tumor, a rare disease, in eligible veteran patients....

Leadiant Biosciences, Inc. was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center, under the Federal Supply Schedule (FSS) Pharmaceuticals and Drugs (FSS-61-IB) contract. The BPA has a $465,000 ceiling value and a performance period through October 2025. The purpose of this BPA is to provide the VA with the chemotherapy drug Matulane. This specialized drug procurement vehicle streamlines the ordering process for VA...

The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Urogen Pharma Inc. The BPA has a potential value of $1.5 million and expires on February 3, 2021. It was established on October 2, 2020 to procure Jelmyto, a treatment for low-grade upper tract urothelial cancer. As the sole awardee, Urogen Pharma will provide its product Jelmyto to the VA National Acquisition Center through this BPA. Jelmyto is an FDA-approved medication for the...

The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Kyowa Kirin, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the procurement of "Drugs, Pharmaceuticals, & Hematology Related Products." This FSS contract has a potential ceiling value of $17,788,800 and a period of performance through September 29, 2027. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase...

The Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network 15 has awarded a Blanket Purchase Agreement (BPA) to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The BPA, valued at $1,493,220.26, is for the delivery of the radiopharmaceutical product PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan) over the contract period ending July 31, 2025. Advanced...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 15 awarded a single award blanket purchase agreement to Advanced Accelerator Applications USA Inc. to provide PLUVICTO and LUTATHERA radiopharmaceuticals. With a period of performance from December 1, 2022 through November 30, 2023 and a value of approximately $4.37 million, this firm fixed price contract utilizes Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs. Performance will take...

Eiger Biopharmaceuticals, Inc. holds a multiple-award Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) under the GSA Pharmaceuticals and Drugs schedule. This $225,000 contract allows Eiger to provide drugs, pharmaceuticals, and hematology-related products to VA medical facilities through January 2027. Under this FSS contract, the VA National Acquisition Center has awarded two single-award Blanket Purchase Agreements (BPAs) to Eiger. The first is a $204,359.25...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center (NAC), a civilian federal agency, to Merck Sharp & Dohme LLC, doing business as Merck, a prominent pharmaceutical manufacturer. The $15,000,000 BPA is for the procurement of the cancer drug Welireg (belzutifan) and does not utilize any set-aside designations, indicating an open and competitive award process. The BPA has an ultimate completion date of July 7, 2025 and was awarded on August 9, 2022. Merck, a...